Dimensional Fund Advisors LP Has $3.76 Million Position in Medifast, Inc. (NYSE:MED)

Dimensional Fund Advisors LP trimmed its position in Medifast, Inc. (NYSE:MED - Free Report) by 8.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 213,134 shares of the specialty retailer's stock after selling 19,719 shares during the period. Dimensional Fund Advisors LP owned 1.95% of Medifast worth $3,756,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of MED. Wells Fargo & Company MN lifted its stake in shares of Medifast by 23.5% in the 4th quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer's stock valued at $114,000 after acquiring an additional 1,227 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Medifast by 2,308.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,442 shares of the specialty retailer's stock valued at $202,000 after acquiring an additional 10,967 shares during the last quarter. Barclays PLC lifted its stake in shares of Medifast by 15.1% in the 4th quarter. Barclays PLC now owns 16,194 shares of the specialty retailer's stock valued at $285,000 after acquiring an additional 2,127 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Medifast by 4.1% in the 4th quarter. Exchange Traded Concepts LLC now owns 17,106 shares of the specialty retailer's stock valued at $301,000 after acquiring an additional 674 shares during the last quarter. Finally, Amundi bought a new position in shares of Medifast in the 4th quarter valued at $374,000. 95.51% of the stock is currently owned by institutional investors.

Medifast Price Performance

NYSE MED traded down $0.01 on Monday, reaching $13.98. The company had a trading volume of 344,710 shares, compared to its average volume of 298,991. The firm has a market cap of $153.65 million, a price-to-earnings ratio of 77.67 and a beta of 0.96. Medifast, Inc. has a fifty-two week low of $11.57 and a fifty-two week high of $26.53. The business has a 50 day moving average of $13.14 and a two-hundred day moving average of $15.60.

Medifast (NYSE:MED - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The specialty retailer reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.04). The company had revenue of $115.73 million during the quarter, compared to analyst estimates of $114.85 million. Medifast had a net margin of 0.35% and a return on equity of 10.64%. As a group, research analysts predict that Medifast, Inc. will post 0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MED. DA Davidson decreased their price objective on Medifast from $17.00 to $16.50 and set a "neutral" rating for the company in a report on Wednesday, February 19th. StockNews.com upgraded Medifast from a "hold" rating to a "buy" rating in a report on Thursday, May 1st.

Medifast Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.